Cas No.: | 170787-99-2 |
Chemical Name: | Efaproxiral sodium |
Synonyms: | Sodium 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoate;Sodium 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoate;Efaproxiral sodium;RSR13 sodium;sodium,2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoate;Revaproxyn;RSR-13;2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic Acid Sodium Salt;Unii-3L83qp52xi;Efaproxiral (sodiuM salt forM);2-[4-[2-(3,5-Dimethylphenylamino)-2-oxoethyl]phenoxy]-2-methylpropionic acid;2-(4-(2-((3,5-Dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoic acid monosodium salt;Propanoic acid, 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methyl-, monosodium salt;Efaproxiral (sodium);RSR 13 sodium;Efaproxiral sodium [USAN];3L83QP52XI;AK116105;Efaproxiral sodium, 98%;Efaproxiral sodium (USAN);Efaproxiral Sodium;sodium 2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoate;2-(4-(2-((3,5-dimethylphe |
SMILES: | [Na+].O(C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])C(N([H])C1C([H])=C(C([H])([H])[H])C([H])=C(C([H])([H])[H])C=1[H])=O)C(C(=O)[O-])(C([H])([H])[H])C([H])([H])[H] |
Formula: | C20H22NNaO4 |
M.Wt: | 363.3828 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Efaproxiral sodium is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT. |
References: | [1]. Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784 |